$ICU
SeaStar Medical Holding Corp Stock $icu

$icu Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024044855 Filed on April 16, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.253M	$1.868M	$2.800M
YoY Change	-19.54%	-62.79%	508.7%
% of Gross Profit
Research & Development	$1.697M	$1.075M	$1.784M
YoY Change	-4.88%	-14.68%	402.54%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$3.950M	$2.943M	$4.581M
YoY Change	-13.77%	-61.88%	1995.03%
Operating Profit	-$3.950M		-$4.581M
YoY Change	-13.77%		464.16%
Interest Expense	$143.0K	-$959.0K	$433.0K
YoY Change	-66.97%	-27.89%	-87.99%
% of Operating Profit
Other Income/Expense, Net	-$8.747M	-$5.978M	-$681.0K
YoY Change	1184.43%	-41.22%	254.69%
Pretax Income	-$12.70M	-$9.880M	-$5.262M
YoY Change	141.3%	-48.6%	-255.4%
Income Tax	$0.00	-$5.000K	$0.00
% Of Pretax Income
Net Earnings	-$12.70M	-$9.875M	-$5.262M
YoY Change	141.3%	-48.62%	-255.4%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.19		-$0.40
Diluted Earnings Per Share	-$0.19	-$0.26	-$0.40
COMMON SHARES
Basic Shares Outstanding	75.42M	36.98M	13.30M
Diluted Shares Outstanding	67.11M		13.03M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.019M	$176.0K	$730.0K
YoY Change	587.53%	252.0%	728.98%
Cash & Equivalents	$5.019M	$176.0K	$725.0K
Short-Term Investments
Other Short-Term Assets	$1.518M	$2.132M	$2.660M
YoY Change	-42.93%	-28.46%	-97.49%
Inventory
Prepaid Expenses	$1.518M	$2.132M	$2.659M
Receivables		$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$6.537M	$2.308M	$3.384M
YoY Change	93.17%	-23.98%	-96.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.203M	$1.205M	$0.00
YoY Change		-30.35%
Total Long-Term Assets	$1.203M	$1.205M	$2.000K
YoY Change	60050.0%	-30.39%
TOTAL ASSETS
Total Short-Term Assets	$6.537M	$2.308M	$3.384M
Total Long-Term Assets	$1.203M	$1.205M	$2.000K
Total Assets	$7.740M	$3.513M	$3.386M
YoY Change	128.59%	-26.31%	-96.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.879M	$4.372M	$3.022M
YoY Change	28.36%	126.88%	1411.0%
Accrued Expenses	$1.544M	$1.523M	$1.531M
YoY Change	0.85%	-32.16%	394.72%
Deferred Revenue		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$1.492M	$4.744M	$493.0K
YoY Change	202.64%	302.72%	-79.96%
Total Short-Term Liabilities	$9.648M	$13.05M	$8.036M
YoY Change	20.06%	143.85%	6.15%
LONG-TERM LIABILITIES
Long-Term Debt	$2.565M	$4.337M	$5.750M
YoY Change	-55.39%	-43.31%
Other Long-Term Liabilities			$490.0K
YoY Change			716.67%
Total Long-Term Liabilities	$2.565M	$4.337M	$6.240M
YoY Change	-58.89%	-43.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.648M	$13.05M	$8.036M
Total Long-Term Liabilities	$2.565M	$4.337M	$6.240M
Total Liabilities	$12.21M	$17.38M	$14.27M
YoY Change	-14.41%	33.69%	88.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$127.4M	-$114.7M	-$104.6M
YoY Change	21.81%	15.48%
Common Stock	$8.000K	$5.000K	$1.000K
YoY Change	700.0%	400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.473M	-$13.87M	-$10.88M
YoY Change
Total Liabilities & Shareholders Equity	$7.740M	$3.513M	$3.386M
YoY Change	128.59%	-26.31%	-96.8%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q1
OPERATING ACTIVITIES
Net Income	-$12.70M	-$9.875M	-$5.262M
YoY Change	141.3%	-48.62%	-255.4%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.488M	-$4.485M	-$2.294M
YoY Change	52.05%	-15.38%	738.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.331M	4.588M	2.972M
YoY Change	180.32%	-13.43%	858.71%
NET CHANGE
Cash From Operating Activities	-3.488M	-4.485M	-2.294M
Cash From Investing Activities
Cash From Financing Activities	8.331M	4.588M	2.972M
Net Change In Cash	4.843M	103.0K	678.0K
YoY Change	614.31%	11059540787199900.0%	1757.69%
FREE CASH FLOW
Cash From Operating Activities	-$3.488M	-$4.485M	-$2.294M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001831868
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39927
CY2023	dei	Entity Registrant Name EntityRegistrantName	SEASTAR MEDICAL HOLDING CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-3681132
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3513 Brighton Blvd.,
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1178000
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4179000
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0
CY2023Q4	icu	Forward Purchase Agreement Derivative Liability ForwardPurchaseAgreementDerivativeLiability	0
CY2022Q4	icu	Forward Purchase Agreement Derivative Liability ForwardPurchaseAgreementDerivativeLiability	10211000
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 410
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80216
CY2023	dei	City Area Code CityAreaCode	844
CY2023	dei	Local Phone Number LocalPhoneNumber	427-8100
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	24232239
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75419458
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023	dei	Auditor Name AuditorName	Armanino LLP
CY2023	dei	Auditor Location AuditorLocation	Bellevue, Washington
CY2023Q4	us-gaap	Cash Cash	176000
CY2022Q4	us-gaap	Cash Cash	47000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2132000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1460000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2308000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1519000
CY2023Q4	us-gaap	Other Assets OtherAssets	1205000
CY2022Q4	us-gaap	Other Assets OtherAssets	1519000
CY2023Q4	us-gaap	Assets Assets	3513000
CY2022Q4	us-gaap	Assets Assets	3038000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4372000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1927000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1523000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2245000
CY2023Q4	icu	Contingent Upfront Payment For License Agreement ContingentUpfrontPaymentForLicenseAgreement	100000
CY2022Q4	icu	Contingent Upfront Payment For License Agreement ContingentUpfrontPaymentForLicenseAgreement	0
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	565000
CY2023Q4	icu	Liability Classified Warrants LiabilityClassifiedWarrants	2307000
CY2022Q4	icu	Liability Classified Warrants LiabilityClassifiedWarrants	587000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13046000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16148000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4143000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	7652000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	194000
CY2023Q4	us-gaap	Liabilities Liabilities	17383000
CY2022Q4	us-gaap	Liabilities Liabilities	23800000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47615285
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47615285
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12699668
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12699668
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100859000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67739000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114734000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88502000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-13870000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-20762000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3513000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3038000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5973000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2503000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8237000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6916000
CY2023	icu	Origination Cost Of Prepaid Forward Contracts OriginationCostOfPrepaidForwardContracts	0
CY2022	icu	Origination Cost Of Prepaid Forward Contracts OriginationCostOfPrepaidForwardContracts	2190000
CY2023	us-gaap	Operating Expenses OperatingExpenses	14210000
CY2022	us-gaap	Operating Expenses OperatingExpenses	11609000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14210000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11609000
CY2023	us-gaap	Interest Expense InterestExpense	1081000
CY2022	us-gaap	Interest Expense InterestExpense	630000
CY2023	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-5380000
CY2022	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	0
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-545000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10863000
CY2023	icu	Change In Fair Value Of Notes Payable Derivative Liability ChangeInFairValueOfNotesPayableDerivativeLiability	0
CY2022	icu	Change In Fair Value Of Notes Payable Derivative Liability ChangeInFairValueOfNotesPayableDerivativeLiability	-602000
CY2023	icu	Change In The Fair Value Of The Forward Purchase Agreement Derivative Liability ChangeInTheFairValueOfTheForwardPurchaseAgreementDerivativeLiability	1308000
CY2022	icu	Change In The Fair Value Of The Forward Purchase Agreement Derivative Liability ChangeInTheFairValueOfTheForwardPurchaseAgreementDerivativeLiability	10211000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4949000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Other Income OtherIncome	151000
CY2022	us-gaap	Other Income OtherIncome	0
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12022000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-580000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26232000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12189000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000
CY2023	us-gaap	Profit Loss ProfitLoss	-26232000
CY2022	us-gaap	Profit Loss ProfitLoss	-12190000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21670330
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21670330
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8211256
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8211256
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2816000
CY2022Q4	icu	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	3294000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	5989000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5744000
CY2022	icu	Issuance Of Liability Classified Warrants IssuanceOfLiabilityClassifiedWarrants	10194000
CY2022	icu	Forward Purchase Agreement Prepayment ForwardPurchaseAgreementPrepayment	-11900000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1311000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12190000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-20762000
CY2023	icu	Stock Issued During Period Value Equity Line Of Credit StockIssuedDuringPeriodValueEquityLineOfCredit	4742000
CY2023	icu	Stock Issued During Period Value Commitment Fee For Equity Line StockIssuedDuringPeriodValueCommitmentFeeForEquityLine	1000000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10411000
CY2023	icu	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1652000
CY2023	icu	Stock Issued During Period Value Prepaid Forward Contracts StockIssuedDuringPeriodValuePrepaidForwardContracts	1870000
CY2023	icu	Forward Purchase Agreement Derivative Liabilities ForwardPurchaseAgreementDerivativeLiabilities	11519000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1930000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26232000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-13870000
CY2023	us-gaap	Profit Loss ProfitLoss	-26232000
CY2022	us-gaap	Profit Loss ProfitLoss	-12190000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	242000
CY2023	icu	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	48000
CY2022	icu	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	0
CY2023	icu	Non Cash Accrued Interest Added To Principal Of Convertible Notes NonCashAccruedInterestAddedToPrincipalOfConvertibleNotes	0
CY2022	icu	Non Cash Accrued Interest Added To Principal Of Convertible Notes NonCashAccruedInterestAddedToPrincipalOfConvertibleNotes	-341000
CY2023	icu	Increase Decrease In Notes Payable IncreaseDecreaseInNotesPayable	0
CY2022	icu	Increase Decrease In Notes Payable IncreaseDecreaseInNotesPayable	602000
CY2023	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	-5380000
CY2022	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	0
CY2023	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	1308000
CY2022	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	10211000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-545000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10863000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4949000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1930000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1311000
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-12000
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-4000
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	97000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1073000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2445000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1548000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	517000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2073000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10285000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7794000
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8000000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1681000
CY2023	icu	Proceeds From Recapitalization ProceedsFromRecapitalization	0
CY2022	icu	Proceeds From Recapitalization ProceedsFromRecapitalization	9961000
CY2023	icu	Payment Of Recapitalization Transaction Costs PaymentOfRecapitalizationTransactionCosts	0
CY2022	icu	Payment Of Recapitalization Transaction Costs PaymentOfRecapitalizationTransactionCosts	1211000
CY2023	icu	Proceeds From Private Investment In Public Equity Investors ProceedsFromPrivateInvestmentInPublicEquityInvestors	0
CY2022	icu	Proceeds From Private Investment In Public Equity Investors ProceedsFromPrivateInvestmentInPublicEquityInvestors	7000000
CY2023	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0
CY2022	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	11940000
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	400000
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4742000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	592000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2023	icu	Proceeds From Additional Warrants ProceedsFromAdditionalWarrants	180000
CY2022	icu	Proceeds From Additional Warrants ProceedsFromAdditionalWarrants	0
CY2023	icu	Payment Of Commitment Fee Equity Line Of Credit PaymentOfCommitmentFeeEquityLineOfCredit	500000
CY2022	icu	Payment Of Commitment Fee Equity Line Of Credit PaymentOfCommitmentFeeEquityLineOfCredit	0
CY2023	icu	Proceeds From Sale Of Recycled Shares ProceedsFromSaleOfRecycledShares	1870000
CY2022	icu	Proceeds From Sale Of Recycled Shares ProceedsFromSaleOfRecycledShares	40000
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	800000
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1878000
CY2023	icu	Payment Of Notes Payable PaymentOfNotesPayable	4870000
CY2022	icu	Payment Of Notes Payable PaymentOfNotesPayable	15000
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	63000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10414000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7331000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	129000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-463000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	510000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47000
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1126000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	6000
CY2023	icu	Value Of Derivative Liability On Issuance Of Convertible Notes ValueOfDerivativeLiabilityOnIssuanceOfConvertibleNotes	0
CY2022	icu	Value Of Derivative Liability On Issuance Of Convertible Notes ValueOfDerivativeLiabilityOnIssuanceOfConvertibleNotes	52000
CY2023	icu	Noncashconversion Of Accrued Expenses Into Convertible Notes NoncashconversionOfAccruedExpensesIntoConvertibleNotes	0
CY2022	icu	Noncashconversion Of Accrued Expenses Into Convertible Notes NoncashconversionOfAccruedExpensesIntoConvertibleNotes	96000
CY2023	icu	Conversion Of Notes Payable To Common Stock ConversionOfNotesPayableToCommonStock	0
CY2022	icu	Conversion Of Notes Payable To Common Stock ConversionOfNotesPayableToCommonStock	5989000
CY2023	icu	Recapitalization Transaction Costs In Accounts Payable RecapitalizationTransactionCostsInAccountsPayable	0
CY2022	icu	Recapitalization Transaction Costs In Accounts Payable RecapitalizationTransactionCostsInAccountsPayable	294000
CY2023	icu	Recapitalization Transaction Cost In Notes Payable RecapitalizationTransactionCostInNotesPayable	0
CY2022	icu	Recapitalization Transaction Cost In Notes Payable RecapitalizationTransactionCostInNotesPayable	2209000
CY2023	icu	Shares Issued As Payment Of Convertible Notes SharesIssuedAsPaymentOfConvertibleNotes	10411000
CY2022	icu	Shares Issued As Payment Of Convertible Notes SharesIssuedAsPaymentOfConvertibleNotes	0
CY2023	icu	Shares Issued To Settle Forward Option Prepaid Forward Contracts SharesIssuedToSettleForwardOptionPrepaidForwardContracts	1870000
CY2022	icu	Shares Issued To Settle Forward Option Prepaid Forward Contracts SharesIssuedToSettleForwardOptionPrepaidForwardContracts	0
CY2023	icu	Issuance Of Convertible Note Warrant IssuanceOfConvertibleNoteWarrant	2705000
CY2022	icu	Issuance Of Convertible Note Warrant IssuanceOfConvertibleNoteWarrant	0
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114700000
CY2023Q4	us-gaap	Cash Cash	200000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include the valuation of the liability classified warrants, prepaid forward purchase agreement derivative liability, provision for income taxes, convertible debt measured at fair value, and the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of credit risk. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.</span></p>
CY2023	icu	Minimum Threshold Percentage For Recognizing Benefit Of Uncertain Income Tax Position MinimumThresholdPercentageForRecognizingBenefitOfUncertainIncomeTaxPosition	0.50
CY2023	icu	Minimum Threshold Percentage Of Income Tax Benefit For Settlement With Tax Authority MinimumThresholdPercentageOfIncomeTaxBenefitForSettlementWithTaxAuthority	0.50
CY2022Q4	us-gaap	Cash Cash	47000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1460000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1519000
CY2022Q4	icu	Prepaid Forward Contracts PrepaidForwardContracts	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1311000
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-4000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1073000
CY2022Q4	us-gaap	Other Assets OtherAssets	1519000
CY2022Q4	us-gaap	Assets Assets	3038000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1927000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2245000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1178000
CY2022Q4	icu	Forward Purchase Agreements Derivative Liability ForwardPurchaseAgreementsDerivativeLiability	10211000
CY2022Q4	icu	Liability Classified Warrants LiabilityClassifiedWarrants	587000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16148000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	7652000
CY2022Q4	us-gaap	Liabilities Liabilities	23800000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67739000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88502000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-20762000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3038000
CY2022Q4	icu	Forward Purchase Agreement To Purchase Remaining Unsold Shares Price Per Share ForwardPurchaseAgreementToPurchaseRemainingUnsoldSharesPricePerShare	10.37
CY2022Q4	icu	Forward Purchase Agreement To Unsold Shares Additional Cash Consideration In The Event Of Delisted ForwardPurchaseAgreementToUnsoldSharesAdditionalCashConsiderationInTheEventOfDelisted	2.5
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2503000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6916000
CY2022	icu	Origination Cost Of Prepaid Forward Contracts OriginationCostOfPrepaidForwardContracts	2190000
CY2022	us-gaap	Operating Expenses OperatingExpenses	11609000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11609000
CY2022	us-gaap	Other Income OtherIncome	0
CY2022	us-gaap	Interest Expense InterestExpense	630000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10863000
CY2022	icu	Change In Fair Value Of Notes Payable Derivative Liability ChangeInFairValueOfNotesPayableDerivativeLiability	-602000
CY2022	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	10211000
CY2022	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	0
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-580000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12189000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000
CY2022	us-gaap	Profit Loss ProfitLoss	-12190000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8211256
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8211256
CY2022Q4	icu	Forward Purchase Agreement To Purchase Remaining Unsold Shares Price Per Share ForwardPurchaseAgreementToPurchaseRemainingUnsoldSharesPricePerShare	10.37
CY2022Q4	icu	Forward Purchase Agreement To Unsold Shares Additional Cash Consideration In The Event Of Delisted ForwardPurchaseAgreementToUnsoldSharesAdditionalCashConsiderationInTheEventOfDelisted	2.5
CY2022	us-gaap	Profit Loss ProfitLoss	-12190000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	242000
CY2022	icu	Non Cash Accrued Interest Added To Principal Of Convertible Notes NonCashAccruedInterestAddedToPrincipalOfConvertibleNotes	-341000
CY2022	icu	Increase Decrease In Notes Payable IncreaseDecreaseInNotesPayable	602000
CY2022	icu	Change In Fair Value Of Forward Purchase Agreement Settlement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementSettlementDerivativeLiability	10211000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10863000
CY2022	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	0
CY2023Q4	icu	Forward Purchase Agreement To Purchase Remaining Unsold Shares Price Per Share ForwardPurchaseAgreementToPurchaseRemainingUnsoldSharesPricePerShare	10.37
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1548000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2073000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7794000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1681000
CY2022	icu	Proceeds From Recapitalization ProceedsFromRecapitalization	9961000
CY2022	icu	Payment Of Recapitalization Transaction Costs PaymentOfRecapitalizationTransactionCosts	1211000
CY2022	icu	Proceeds From Private Investment In Public Equity Investors ProceedsFromPrivateInvestmentInPublicEquityInvestors	7000000
CY2022	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	11940000
CY2022	icu	Proceeds From Sale Of Recycled Shares ProceedsFromSaleOfRecycledShares	40000
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1878000
CY2022	icu	Payment Of Notes Payable PaymentOfNotesPayable	15000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	63000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7331000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-463000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	510000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47000
CY2022Q4	icu	Forward Purchase Agreement To Purchase Remaining Unsold Shares Price Per Share ForwardPurchaseAgreementToPurchaseRemainingUnsoldSharesPricePerShare	10.37
CY2022Q4	icu	Forward Purchase Agreement To Unsold Shares Additional Cash Consideration In The Event Of Delisted ForwardPurchaseAgreementToUnsoldSharesAdditionalCashConsiderationInTheEventOfDelisted	2.5
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2816000
CY2022Q4	icu	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	3294000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	5989000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5744000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10194000
CY2022	icu	Adjustments To Additional Paid In Capital Prepaid Forward Purchase Agreement AdjustmentsToAdditionalPaidInCapitalPrepaidForwardPurchaseAgreement	11900000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1311000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12190000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-20762000
CY2022Q4	icu	Forward Purchase Agreements Derivative Liability ForwardPurchaseAgreementsDerivativeLiability	5200000
CY2022Q4	icu	Additional Forward Purchase Agreement Liabilities AdditionalForwardPurchaseAgreementLiabilities	5000000
CY2023	icu	Additional Loss In Forward Purchase Agreements Due To Change In Stock Price AdditionalLossInForwardPurchaseAgreementsDueToChangeInStockPrice	2300000
CY2023Q1	icu	Gain Loss On Settlement Of Forward Purchase Agreements GainLossOnSettlementOfForwardPurchaseAgreements	1000000
CY2023Q1	icu	Reclassified Equity Value As A Result Settlement Of Forward Purchase Agreements ReclassifiedEquityValueAsAResultSettlementOfForwardPurchaseAgreements	11500000
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	501000
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	450000
CY2023Q4	icu	Accrued Director Compensation Current AccruedDirectorCompensationCurrent	427000
CY2022Q4	icu	Accrued Director Compensation Current AccruedDirectorCompensationCurrent	61000
CY2023Q4	icu	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	507000
CY2022Q4	icu	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	0
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	43000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	19000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	112000
CY2023Q4	icu	Accrued Commitment Fee Equity Line Of Credit AccruedCommitmentFeeEquityLineOfCredit	0
CY2022Q4	icu	Accrued Commitment Fee Equity Line Of Credit AccruedCommitmentFeeEquityLineOfCredit	1500000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	26000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	122000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1523000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2245000
CY2023	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	500000
CY2023Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	95300000
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	52000
CY2023Q4	us-gaap	Notes Payable NotesPayable	4708000
CY2022Q4	us-gaap	Notes Payable NotesPayable	8830000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	565000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1178000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	4143000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	7652000
CY2023Q4	icu	Future Maturities Of Principal Repayment Of Convertible Notes Next Twelve Months FutureMaturitiesOfPrincipalRepaymentOfConvertibleNotesNextTwelveMonths	565000
CY2023Q4	icu	Future Maturities Of Principal Repayment Of Convertible Notes Year Two FutureMaturitiesOfPrincipalRepaymentOfConvertibleNotesYearTwo	4143000
CY2023Q4	icu	Future Maturities Of Principal Repayment Of Convertible Notes Due FutureMaturitiesOfPrincipalRepaymentOfConvertibleNotesDue	4708000
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000
CY2020Q2	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	3000
CY2020Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0375
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	23205203
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	16857714
CY2023Q1	icu	Issuance Of Convertible Notes IssuanceOfConvertibleNotes	2900000
CY2022Q4	icu	Shares Authorized SharesAuthorized	110000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of common stock are entitled to one voter per share on matters to be voted on by stockholders.
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	32000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	32000
CY2023Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	200000
CY2022Q4	icu	Trading Days TradingDays	30
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0326
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0441
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0065
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Meals And Entertainment EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment	-0.0002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0026
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002
CY2023	icu	Effective Income Tax Rate Reconciliation Interest On Convertible Notes EffectiveIncomeTaxRateReconciliationInterestOnConvertibleNotes	-0.0087
CY2022	icu	Effective Income Tax Rate Reconciliation Interest On Convertible Notes EffectiveIncomeTaxRateReconciliationInterestOnConvertibleNotes	-0.0107
CY2023	icu	Effective Income Tax Rate Reconciliation Unrealized Gains And Losses Net For Liability Classified Derivatives Percent EffectiveIncomeTaxRateReconciliationUnrealizedGainsAndLossesNetForLiabilityClassifiedDerivativesPercent	-0.0611
CY2022	icu	Effective Income Tax Rate Reconciliation Unrealized Gains And Losses Net For Liability Classified Derivatives Percent EffectiveIncomeTaxRateReconciliationUnrealizedGainsAndLossesNetForLiabilityClassifiedDerivativesPercent	0.001
CY2023	icu	Effective Income Tax Rate Reconciliation Fair Value Adjustment Of Convertible Notes And Related Warrants EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfConvertibleNotesAndRelatedWarrants	-0.0393
CY2022	icu	Effective Income Tax Rate Reconciliation Fair Value Adjustment Of Convertible Notes And Related Warrants EffectiveIncomeTaxRateReconciliationFairValueAdjustmentOfConvertibleNotesAndRelatedWarrants	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0455
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0056
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1827
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2478
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21911000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18627000
CY2023Q4	icu	Finance Charges And Origination Fees FinanceChargesAndOriginationFees	602000
CY2022Q4	icu	Finance Charges And Origination Fees FinanceChargesAndOriginationFees	1028000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	232000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	130000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	83000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	311000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1642000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	434000
CY2023Q4	icu	Deferred Tax Assets Capitalizsed Start Up Fees DeferredTaxAssetsCapitalizsedStartUpFees	231000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	903000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	715000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25604000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21245000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25604000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21245000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4800000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5600000
CY2023	icu	Testing Period TestingPeriod	P3Y
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The Company files U.S. federal and state tax returns with varying statutes of limitations. Due to net operating loss and credit carryforwards, the 2019 to 2023 tax years remain subject to examination by the U.S. federal and some state authorities. The actual amount of any taxes due could vary significantly depending on the ultimate timing and nature of any settlement.
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3750000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4581000
CY2023Q3	us-gaap	Interest Expense InterestExpense	-224000
CY2023Q2	us-gaap	Interest Expense InterestExpense	-225000
CY2023Q1	us-gaap	Interest Expense InterestExpense	-433000
CY2023Q3	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-291000
CY2023Q2	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-100000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20281030
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17400895
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26232000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12190000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21670330
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21670330
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8211256
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8211256
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1087000
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1981000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1730000
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1855000
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1769000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2851000
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2942000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	3750000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4581000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2942000
CY2023Q1	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	100000
CY2023Q3	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	0
CY2023Q2	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	910000
CY2023Q1	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	-2218000
CY2023Q3	icu	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	1025000
CY2023Q2	icu	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	723000
CY2023Q1	icu	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	36000
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4949000
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023Q3	us-gaap	Other Income OtherIncome	149000
CY2023Q2	us-gaap	Other Income OtherIncome	0
CY2023Q1	us-gaap	Other Income OtherIncome	0
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4290000
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1308000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2515000
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7232000
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2442000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7096000
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-7232000
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2447000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-7096000
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20048473
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20048473
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14932866
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14932866
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13025852
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13025852
CY2023Q1	us-gaap	Cash Cash	725000
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1481000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2206000
CY2023Q1	us-gaap	Other Assets OtherAssets	1441000
CY2023Q1	us-gaap	Assets Assets	3647000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3022000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1792000
CY2023Q1	icu	Contingent Upfront Payment For License Agreement ContingentUpfrontPaymentForLicenseAgreement	100000
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	493000
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2390000
CY2023Q1	icu	Forward Purchase Agreement Derivative Liability ForwardPurchaseAgreementDerivativeLiability	12429000
CY2023Q1	icu	Liability Classified Warrants LiabilityClassifiedWarrants	1051000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	21277000
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	5745000
CY2023Q1	icu	Outstanding Forward Contracts OutstandingForwardContracts	0
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-16017000
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2508000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1730000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2851000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4581000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4581000
CY2023Q1	us-gaap	Interest Expense InterestExpense	-433000
CY2023Q1	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	100000
CY2023Q1	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	-2218000
CY2023Q1	icu	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	36000
CY2023Q1	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	0
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2515000
CY2023Q1	us-gaap	Liabilities Liabilities	27022000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72222000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95598000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-23375000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3647000
CY2023Q2	us-gaap	Cash Cash	13000
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1220000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	1233000
CY2023Q2	icu	Prepaid Forward Contracts PrepaidForwardContracts	0
CY2023Q2	us-gaap	Other Assets OtherAssets	1362000
CY2023Q2	us-gaap	Assets Assets	2595000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4355000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1356000
CY2023Q2	icu	Contingent Upfront Payment For License Agreement ContingentUpfrontPaymentForLicenseAgreement	100000
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	5907000
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2230000
CY2023Q2	icu	Liability Classified Warrants LiabilityClassifiedWarrants	403000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	14351000
CY2023Q2	us-gaap	Liabilities Liabilities	14351000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	2000
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86287000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98045000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-11756000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2595000
CY2023Q3	us-gaap	Cash Cash	73000
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1152000
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1225000
CY2023Q3	us-gaap	Other Assets OtherAssets	1283000
CY2023Q3	us-gaap	Assets Assets	2508000
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5042000
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1748000
CY2023Q3	icu	Contingent Upfront Payment For License Agreement ContingentUpfrontPaymentForLicenseAgreement	100000
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4405000
CY2023Q3	icu	Liability Classified Warrants LiabilityClassifiedWarrants	1508000
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12803000
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	5722000
CY2023Q3	us-gaap	Liabilities Liabilities	18525000
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	3000
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89257000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105277000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7096000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-7096000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13025852
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13025852
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1981000
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1769000
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	3750000
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3750000
CY2023Q2	us-gaap	Interest Expense InterestExpense	-225000
CY2023Q2	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-100000
CY2023Q2	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	910000
CY2023Q2	icu	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	723000
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1308000
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2442000
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2447000
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14932866
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14932866
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3711000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4620000
	us-gaap	Operating Expenses OperatingExpenses	8331000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8331000
	us-gaap	Interest Expense InterestExpense	-658000
	icu	Change In Fair Value Of Forward Purchase Agreement Derivative Liability ChangeInFairValueOfForwardPurchaseAgreementDerivativeLiability	-1308000
	icu	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	759000
	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	0
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1207000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9538000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
	us-gaap	Profit Loss ProfitLoss	-9543000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13984625
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13984625
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1087000
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1855000
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2942000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2942000
CY2023Q3	us-gaap	Interest Expense InterestExpense	-224000
CY2023Q3	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-291000
CY2023Q3	icu	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	1025000
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4949000
CY2023Q3	us-gaap	Other Income OtherIncome	149000
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4290000
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7232000
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-7232000
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20048473
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20048473
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4798000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6475000
	us-gaap	Operating Expenses OperatingExpenses	11273000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11273000
	us-gaap	Interest Expense InterestExpense	-882000
	icu	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-291000
	icu	Change In Fair Value Of Forward Option Prepaid Forward Contracts ChangeInFairValueOfForwardOptionPrepaidForwardContracts	1308000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1784000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4949000
	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	0
	us-gaap	Other Income OtherIncome	149000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5497000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16770000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
	us-gaap	Profit Loss ProfitLoss	-16775000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16028118
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16028118
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-7096000
CY2023Q1	icu	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	4000
CY2023Q1	icu	Increase Decrease In Fair Value Of Forward Purchase Agreement Derivative Liability IncreaseDecreaseInFairValueOfForwardPurchaseAgreementDerivativeLiability	2218000
CY2023Q1	icu	Increase Decrease In Fair Value Of Liability Classified Warrants IncreaseDecreaseInFairValueOfLiabilityClassifiedWarrants	-36000
CY2023Q1	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	100000
CY2023Q1	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	0
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	505000
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-12000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-318000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1095000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	786000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2294000
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3000000
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10000
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1108000
CY2023Q1	icu	Payment Of Commitment Fee Equity Line Of Credit PaymentOfCommitmentFeeEquityLineOfCredit	500000
CY2023Q1	icu	Proceeds From Sale Of Recycled Shares ProceedsFromSaleOfRecycledShares	1870000
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000
CY2023Q1	icu	Payment Of Notes Payable PaymentOfNotesPayable	2596000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2972000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	678000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	725000
	us-gaap	Profit Loss ProfitLoss	-9543000
	icu	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	23000
	icu	Increase Decrease In Fair Value Of Forward Purchase Agreement Derivative Liability IncreaseDecreaseInFairValueOfForwardPurchaseAgreementDerivativeLiability	1308000
	icu	Increase Decrease In Fair Value Of Liability Classified Warrants IncreaseDecreaseInFairValueOfLiabilityClassifiedWarrants	-759000
	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	0
	us-gaap	Share Based Compensation ShareBasedCompensation	1060000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-12000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-658000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2428000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	350000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4463000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	258000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1163000
	icu	Payment Of Commitment Fee Equity Line Of Credit PaymentOfCommitmentFeeEquityLineOfCredit	500000
	icu	Proceeds From Sale Of Recycled Shares ProceedsFromSaleOfRecycledShares	1870000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000
	icu	Payment Of Notes Payable PaymentOfNotesPayable	2946000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4429000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13000
	us-gaap	Profit Loss ProfitLoss	-16775000
	icu	Amortization Of Deferred Financing Costs AmortizationOfDeferredFinancingCosts	37000
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	-291000
	icu	Increase Decrease In Fair Value Of Forward Purchase Agreement Derivative Liability IncreaseDecreaseInFairValueOfForwardPurchaseAgreementDerivativeLiability	1308000
	icu	Increase Decrease In Fair Value Of Liability Classified Warrants IncreaseDecreaseInFairValueOfLiabilityClassifiedWarrants	-1784000
	icu	Gain Loss On Sale Of Recycled Shares GainLossOnSaleOfRecycledShares	-0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4949000
	us-gaap	Share Based Compensation ShareBasedCompensation	1544000
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-12000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-805000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3115000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	698000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5800000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6500000
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	282000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1283000
	icu	Payment Of Commitment Fee Equity Line Of Credit PaymentOfCommitmentFeeEquityLineOfCredit	500000
	icu	Proceeds From Sale Of Recycled Shares ProceedsFromSaleOfRecycledShares	1870000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000
	icu	Payment Of Notes Payable PaymentOfNotesPayable	3145000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5826000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	26000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47000
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-20762000
CY2023Q1	icu	Stock Issued During Period Value Equity Line Of Credit StockIssuedDuringPeriodValueEquityLineOfCredit	1108000
CY2023Q1	icu	Stock Issued During Period Value Commitment Fee For Equity Line StockIssuedDuringPeriodValueCommitmentFeeForEquityLine	1000000
CY2023Q1	icu	Stock Issued During Period Value Prepaid Forward Contracts StockIssuedDuringPeriodValuePrepaidForwardContracts	1870000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	505000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7096000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-23375000
CY2023Q2	icu	Stock Issued During Period Value Equity Line Of Credit StockIssuedDuringPeriodValueEquityLineOfCredit	55000
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1937000
CY2023Q2	icu	Stock Issued During Period Value Prepaid Forward Contracts StockIssuedDuringPeriodValuePrepaidForwardContracts	0
CY2023Q2	icu	Adjustments To Additional Paid In Capital Forward Purchase Agreement Derivative Liability AdjustmentsToAdditionalPaidInCapitalForwardPurchaseAgreementDerivativeLiability	11519000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	555000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2447000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-11756000
CY2023Q3	icu	Stock Issued During Period Value Equity Line Of Credit StockIssuedDuringPeriodValueEquityLineOfCredit	120000
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2411000
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	440000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7232000
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-16017000

Files In Submission

Name	View Source	Status
0000950170-24-044855-index-headers.html	Edgar Link	pending
R38.htm	Edgar Link	pending
0000950170-24-044855-index.html	Edgar Link	pending
0000950170-24-044855.txt	Edgar Link	pending
0000950170-24-044855-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
icu-20231231.htm	Edgar Link	pending
icu-20231231.xsd	Edgar Link	pending
icu-ex10_38.htm	Edgar Link	pending
icu-ex23_1.htm	Edgar Link	pending
icu-ex23_2.htm	Edgar Link	pending
icu-ex31_1.htm	Edgar Link	pending
icu-ex31_2.htm	Edgar Link	pending
icu-ex32_1.htm	Edgar Link	pending
icu-ex32_2.htm	Edgar Link	pending
img181588555_0.jpg	Edgar Link	pending
img256118960_0.jpg	Edgar Link	pending
img256118960_1.jpg	Edgar Link	pending
img256118960_2.jpg	Edgar Link	pending
img256118960_3.jpg	Edgar Link	pending
img256118960_4.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
icu-20231231_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICU
SeaStar Medical Holding Corp Stock $icu

2024 Q1 Form 10-K Financial Statement

#000095017024044855 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICU SeaStar Medical Holding Corp Stock $icu

2024 Q1 Form 10-K Financial Statement

#000095017024044855 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICU
SeaStar Medical Holding Corp Stock $icu